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Abstract
Although the mucoid form of Pseudomonas aeruginosa (Pa) is largely responsible for the progression of lung disease in cystic ﬁbrosis
(CF), the relationship between factors relating daily-care regimes to mucoidy acquisition are as yet poorly investigated. Fifty-two CF
patients registered at the CF centre of Dijon, France, were retrospectively evaluated from the date of Pa colonization either to the ﬁrst
positive sputum culture for mucoid Pa (n = 26) or to the last culture in which the Pa remained non-mucoid (n = 26). All clinical, patho-
logical and therapeutic events were recorded. The association between the parameters collected and mucoid transition of Pa was
assessed in a Cox model with time-dependant covariables. The mean follow-up was 4.7 ± 4.3 years. Three independent parameters
were associated with the higher risk of mucoid transition of Pa: persistence of Pa in sputum (OR 7.89; p <0.01), use of inhaled bron-
chodilators (OR 3.40; p = 0.04), and the use of inhaled colimycin (OR 4.04; p = 0.02). Isolation of Staphylococcus aureus, Haemophilus
inﬂuenzae or Streptococcus pneumoniae in sputum was associated with a lower risk (OR 0.24; p < 0.01). Mucoid transition of Pa was
associated with variables that reﬂected the severity of both lung disease and Pa colonization. Although they do not lead to prophylactic
measures, these results corroborate the need to avoid Pa persistence.
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Introduction
Pseudomonas aeruginosa (Pa) is the most common pathogen
involved in cystic ﬁbrosis (CF) lower respiratory tract
infections, and Pa chronic lung infection appears to be of
major clinical signiﬁcance, accounting for an up to 2.6-fold
higher risk of death [2–5]. Pa infection usually evolves in two
successive stages, from initially intermittent infection to
chronic infection [3], and has been considered to be the
main trigger of lung function decline.
Mucoid phenotype of Pa (mPa) appears to be an important
determinant of clinical worsening among Pa infected CF
children [3,6–9]. Alginate production in the mucoid pheno-
type confers resistance to phagocytosis and to antibiotics,
and is responsible for persistent inﬂammation of the airways
[10–12]. Molecular mechanisms underlying mucoid transition
of Pa have been elucidated in vitro and include oxidative
burst, hydrogen peroxide, low oxygen, and high osmolarity
[11,13,14]. Meanwhile, the use of indices in daily-care
programmes as predictors of Pa mucoid transition remain
poorly investigated. The present study aimed to identify fac-
tors associated with mucoid transition that can be monitored
during daily care and which could be targets of care regimes
for preventing or postponing this transition in CF patients
infected by Pa.
Materials and Methods
This is a retrospective study of CF patients followed at the
CF centre of Dijon (France) from October 1986 to June
2005. Patients were considered eligible if Pa had been
identiﬁed in their sputum culture on at least one occasion.
Cases were excluded if they had mPa prior to their follow-
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up at the centre, or if they acquired mPa during a later
follow-up period.
At each follow-up visit at the CF centre, a sputum sample
was collected routinely. Pa was identiﬁed either using the
Api 20NE system (bioMe´rieux, Marcy-l’Etoile, France), or by
resistance to 9-chloro-9-(4-diethyl-aminophenyl)-10-pheny-
lacridan (C-390) and 1,10-phenanthrolin. Mucoid strains were
identiﬁed visually. Chronic colonization was deﬁned by
obtaining at least three Pa-positive sputum samples over
6 months.
The antibiotic treatment regimen was guided according to
the European consensus [15]. Two antibiotics were given in
the case of symptoms of pulmonary exacerbation, in the
form of 10- to 14-day courses. The antibiotic choice
depended on results obtained from microbiology tests
performed on the most recent sputum sample. Severely-ill
patients were regularly treated on the basis of three to four
antibiotic courses per year, with additional courses when
required, and daily inhalation of tobramycin or colimycin.
Non-antibiotic treatment consisted of: physiotherapy, use
of bronchodilators (i.e. inhaled or systemic steroids), rhDN-
Ase, non-steroid anti-inﬂammatories, N-acetyl-cystein and az-
ithromycin, as needed. From 2000 onwards, CF patients
were segregated according to their Pa status, aiming to
prevent cross-infection.
Data collection
For each patient, datasets started from the ﬁrst available
positive sputum culture for non-mucoid Pa at the CF centre
of Dijon. Endpoints were deﬁned by the ﬁrst evidence of
mPa in sputum, the last follow-up visit at the CF centre on
15 June 2005, lung transplantation, or death, whichever
occurred ﬁrst.
The baseline data considered comprised: gender, date of
birth, and CF transmembrane conductance regulator (CFTR)
genotype (number of DF508 alleles). Clinical, functional, path-
ological, biological, microbiological and therapeutic data were
extracted from medical records (Table 1). Weight, size and
body mass index are expressed as the z-score for age [16].
Respiratory function tests were performed once to twice a
year for children aged ‡6 years.
Statistical analysis
Continuous variables are expressed as the mean ± SD.
A chi-square test (qualitative variables) and a t-test (quantita-
tive variables) were used for comparisons. Survival curves
using non-parametric Kaplan–Meier were used for analysis of
mPa occurrence. The independent association of daily-care
variables with mPa acquisition was assessed using a Cox
model with time-dependant covariables. Hazard ratios (HR),
OR and 95% CI were calculated. Including time-dependent
covariables in the model made it possible to use the patients’
baseline information and the data collected at different fol-
low-up visits. Signiﬁcant risk factors were tested in multivari-
ate analysis using stepwise selection, with thresholds of p
values at 0.40 and 0.20. p < 0.05 in the ﬁnal multivariate
model was considered to be statistically signiﬁcant. Analyses
were performed using STATA software, version 8.0 (Stat-
Corp, College Station, TX, USA).
Results
Patient characteristics
A total of 55 CF patients met the inclusion criteria. Three of
them harboured mPa as primo colonization, and were
excluded from analyses because mPa acquisition constituted
an endpoint. For the included patients, the exact date of
non-mucoid Pa acquisition was not known. Among the 52
included patients, 32 were DF508 homozygous, 15 were
DF508 compound heterozygous, and four had other CFTR
mutations (data on CFTR mutations were not available for
one patient). There were 22 males and 30 females. The
mean age at enrollment was 7.5 ± 7.0 years, and the mean
study follow-up time was 4.7 ± 4.3 years.
Mucoid P. aeruginosa acquisition
Half of the patients (n = 26) presented with mucoid transi-
tion of Pa during follow-up (Table 1). The age at inclusion is
the only signiﬁcant difference between children developing
mPa (9.7 ± 7.5 years) and those with Pa remaining non-
mucoid until endpoint (5.4 ± 5.8 years, p = 0.02). In particu-
lar, the mean duration of the follow-up study does not differ
between these two groups (4.8 ± 4.6 vs. 4.7 ± 4.1 years,
respectively, p = 0.91). The median time from enrollment to
mucoid transition is 5.1 ± 1.6 years, as determined from the
Kaplan–Meier survival curve (Fig. 1). Further analyses are
adjusted for age at enrollment.
Association between variables and Pa mucoid transition
The results of univariate analysis are shown in Table 2.
A higher age at enrollment (i.e. at ﬁrst sputum culture posi-
tive for Pa) is signiﬁcantly associated with more frequent
mucoid transition (HR 1.06, 95% CI 1.01–1.12, p = 0.02),
whereas being DF508 homozygote appears to be associated
with a lower risk (OR 0.41, 95% CI 0.19–0.90, p = 0.03).
A mucoid transition of Pa is signiﬁcantly more frequent in
patients with a worse than predicted forced expiratory
volume (FEV)1% (HR 1.33 for a 10% decrease compared
to predicted value, 95% CI 1.05–1.69, p = 0.02), or with
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high ﬁbrinogen plasma level (HR 3.48, 95% CI 1.44–8.18,
p <0.01).
Exposure to anti-pseudomonal systemic antibiotics,
inhalation of colimycin, bronchodilators, and oxygen were
associated with higher risk of mucoid transition (HR 1.12 for a
1-day increase, 95% CI 1.02–1.23, p = 0.01; OR 5.75, 95% CI
2.36–14.01, p < 0.001; OR 3.13, 95% CI 1.30–7.54, p = 0.01
and OR 6.10, 95% CI 1.31–28.34, p = 0.02, respectively).
Chronic airway infection by Pa is signiﬁcantly associated
with more frequent mucoid transition (OR 6.38, 95% CI
2.39–17.01, p < 0.001), particulary when each consecutive
sputum culture remains positive (OR 9.18, 95% CI 2.59–
32.56, p = 0.001). Conversely, the presence of Staphylococcus
aureus in sputum is associated with signiﬁcantly lower
frequencies of mucoid transition of Pa using univariate
analysis (OR 0.43, 95% CI 0.19–0.99, p = 0.05), as is the
presence of S. aureus, Streptococcus pneumoniae or Haemo-
philus inﬂuenzae in sputum (OR 0.20, 95% CI 0.09–0.46,
p < 0.001).
For multivariate analysis, FEV1% and ﬁbrinogen could
not be included as a result of missing data. In the ﬁnal
model, four variables remain signiﬁcant (Table 2). Three
variables were associated with a higher risk of mucoid
transition: persistence of Pa in sputum cultures (OR 7.89,
95% CI 1.78–34.99, p < 0.01), use of inhaled bronchodila-
tors (OR 3.4, 95% CI 1.04–11.12, p = 0.04), and use of
inhaled colimycin (OR 4.04, 95% CI 1.27–12.9, p = 0.02).
As a complementary investigation, we sought to determine
whether the association of mPa transition with inhaled
bronchodilators and colimycin related to levels of
exposure to these treatments; we found no signiﬁcant dif-
ference in overall exposure to bronchodilators, comparing
further absence or presence of mucoid transition of Pa
(61.8% vs. 51.6%, respectively, p = 0.41), or in overall
exposure to inhaled colimycin (21.9% vs. 18.1%,
respectively, p = 0.62). Thus, the highlighted associations in
the Cox model reﬂect the different distribution of bron-
chodilator and colimycin use in time because these treat-
TABLE 1. Study population baseline
characteristics
Mucoid transition
(n = 26)
No mucoid transition
(n = 26) p value
Age at enrollment (years) 9.7 ± 7.5 (0.6 to 25.4) 5.4 ± 5.8 (0.2 to 23.6) 0.02
Sex ratio M/F (n/n) 13/13 9/17 0.26
Mean follow-up duration (years) 4.8 ± 4.6 (0.2 to 17.6) 4.7 ± 4.1 (0.6 to 14.3) 0.91
CFTR genotype (n)
DF508/DF508 13 19
DF508/other 11 4 0.13
Other/other 2 2
Weight (z-score) )0.76 ± 1.31 ()2.91 to 2.29) )0.77 ± 1.25 ()3.25 to 1.50) 0.97
Size (z-score) )0.73 ± 1.11 ()3.03 to 1.33) )0.31 ± 1.30 ()2.93 to 1.93) 0.22
Body mass index (z-score) )0.60 ± 1.16 ()2.12 to 2.20) )0.71 ± 0.91 ()2.45 to 1.70) 0.72
FEV1% predicted (%) 69.6 ± 24.3 (15 to 109) (n = 12) 84.5 ± 15.1 (54 to 103) (n = 9) 0.12
Diabetes mellitus (n) 1 1 1.00
Retinol-binding-protein (mg/l) 29.6 ± 11.9 (13.0 to 48.5) 30.6 ± 5.7 (19.0 to 39.0) 0.51
Albumin (g/l) 41.4 ± 4.0 (33.4 to 47.0) 43.0 ± 3.2 (36.0 to 48.5) 0.19
IgG (g/l) 13.3 ± 3.9 (6.5 to 19.1) 9.9 ± 4.1 (4.1 to 19.0) 0.27
Long-term treatment at
enrollment (n)
Azithromycin 1 0 1.00
Bronchodilators 12 13 0.89
Inhaled tobramycin 1 3 0.61
Inhaled colimycin 2 6 0.25
Inhaled steroids 5 7 0.56
rhDNAse 8 5 0.34
N-acetyl-cystein 3 1 0.61
Oxygenotherapy 2 1 1.00
CFTR, cystic ﬁbrosis transmembrane conductance regulator; FEV1% predicted, percentage of predicted forced expira-
tory volume in 1 s.
Continuous values are expressed as the mean ± SD (extreme values).
Statistically signiﬁcant value is highlighted in bold.
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FIG. 1. Cumulative survival free of mucoid Pseudomonas aeruginosa
among subjects infected by P. aeruginosa (n = 52).
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ments were mainly introduced shortly before Pa turns to
mucoid phenotype.
By contrast, sputum cultures positive for S. aureus,
S. pneumoniae or H. inﬂuenzae were associated with lower
rates of mucoid transition, with the OR of 0.24 (95% CI 0.09–
0.67, p <0.01), irrespective of the presence of Pa. Children
with Pa who remained non-mucoid always harboured at least
one of these three bacteria throughout follow-up, whereas
nine children acquiring mPa had their sputum culture cleared
of these bacteria before mucoid transition of Pa. Overall, for
children with Pa remaining non-mucoid, colonization by
S. aureus, S. pneumoniae and H. inﬂuenzae was 78.2%, 15.9%
and 32.7% respectively, compared to 67.1%, 13.5% and 31.2%,
respectively in children with mucoid transition (p 0.02, p 0.61
and p 0.83, respectively). Neither age at enrollment, DF508
homozygote genotype, gender, nor use of anti-pseudomonal
antibiotics was associated with Pa mucoid transition.
Discussion
Until recently [17], the available data were scarce with
respect to predictors of mPa transition, although it is widely
believed that mPa airway infection is a dramatically pejorative
event. Three out of 55 children in the present study were
colonized with mucoid phenotype, which is similar to data in
the literature reporting immediate mucoid phenotype at
frequencies of up to 10% [18]. For these three particular
TABLE 2. Univariate and multi-
variate Cox models for associa-
tion with mucoid transition of
Pseudomonas aeruginosa
Univariate analysis Multivariate analysis
HR/OR (95% CI) p value HR/OR (95% CI) p value
Gender: male vs. female OR 1.13 0.749
Age at enrollment (years) HR 1.06 (1.01–1.12) 0.02 HR 1.06 NS
DF508 homozygote OR 0.41 (0.19–0.90) 0.03 Ruled out
Body mass index (z-score) HR 0.74 0.18
FEV1% predicted (HR for 10% decrease) HR 1.33 (1.05–1.69) 0.02
Diabetes mellitus OR 1.50 0.59
Biological parameters
IgG (g/l) HR 1.11 0.12
Fibrinogen (g/l) HR 3.38 (1.44–8.18) <0.01
RBP (mg/l) HR 0.97 0.53
Antibiotic systemic courses
Any antibiotics
Presence OR 1.04 0.94
Number days/month (days) HR 1.03 0.43
Any antibiotics
Presence OR 0.46 0.11
Number days/month (days) HR 0.98 0.78
Anti-pseudomonal
Presence OR 2.42 (1.04–5.62) 0.04
Number days/month (days) HR 1.12 (1.02–1.23) 0.01 Ruled out
Other treatment
Azithromycin OR 2.46 0.18
Inhaled bronchodilators OR 3.13 (1.30–7.54) 0.01 OR 3.40 (1.04–11.12) 0.04
Inhaled colimycin OR 5.75 (2.36–14.01) <0.001 OR 4.04 (1.27–12.9) 0.02
Inhaled steroids OR 0.97 0.94
rhDNAse OR 1.47 0.36
NAC OR 1.24 0.70
Oxygen OR 6.10 (1.31–28.34) 0.02
Inhaled tobramycin OR 1.87 0.22
Pseudomonas aeruginosa colonization
Concentration (Log CFU m/l) HR 1.23 0.20
Persistence compared to previous
sputum
OR 9.18 (2.59–32.56) <0.01 OR 7.89 (1.78–34.99) <0.01
Chronic colonization OR 6.38 (2.39–17.01) <0.001
Other bacteria
Achromobacter sp. OR 2.09 0.10
Burkholderia sp. OR 2.59 0.05
Haemophilus inﬂuenzae OR 0.76 0.52
Staphylococcus aureus OR 0.43 (0.19–0.99) 0.05
Streptococcus pneumoniae OR 0.86 0.74
Stenotrophomonas maltophilia OR 1.68 0.24
Presence of Haemophilus inﬂuenzae,
Staphylococcus aureus or
Streptococcus pneumoniae
OR 0.20 (0.09–0.46) <0.001 OR 0.24 (0.09–0.67) <0.01
FEV1%, percentage of forced expiratory volume in 1 s; RBP, retinol binding protein; Number days/month, number of
days of treatment per month; CFU, colony forming unit; NAC, N-acetyl cystein, NS, non-signiﬁcant.
Hazard ratios (HR) are expressed for a one unit increment, excepted for FEV1%: HR for a 10% decrease. Due to
missing data, FEV1% and ﬁbrinogen plasma level were not included in the model. Signiﬁcant results are expressed as
HR/OR (95% CI).
Statistically signiﬁcant values are highlighted in bold.
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children, no common pattern was found after a detailed
analysis of medical records: cross-infection is thus the most
probable hypothesis [19].
Data from reports in the literature reveal considerable
variation in the delay between Pa primo colonization and
mucoid transition, from less than 1 month to more than
5 years, with a mean of 1–3 years [9,18]. One large
prospective study even relates a median time of 10.9 years
[3]. This is consistent with the median delay of 5.1 years
obtained in the present study, which spanned from
immediate mucoid phenotype to 14.5 years.
Li et al. [3] demonstrated that anti-pseudomonal antibiotics
can reduce and postpone Pa mucoid transition. Interestingly,
our multivariate analysis showed no signiﬁcant association
between mucoid transition and anti-pseudomonal antibiotics;
rather, our univariate analysis suggests an increased risk of
mucoid transition. Parad et al. [8] also highlighted the protec-
tive effect of mucoid exopolysaccharide speciﬁc opsonizing
antibodies. Unfortunately, this parameter could not be investi-
gated in the present study because serological tests were not
routinely available at the time that the clinical records were
taken. Furthermore, in this retrospective study, we were
unable to explore the impact of the duration of Pa colonization
before the mucoid transition.
The relative ‘protective effect’ of the colonization by
S. aureus [17], S. pneumoniae or H. inﬂuenzae in sputum, against
mucoid transition of Pa, reﬂects the classic evolution of CF
lung infection [20]. Typically, the respiratory tract is
successively colonized by ‘respiratory’ bacteria, followed by
S. aureus, and then ﬁnally Pa, which initially colonizes along
with other bacteria, before excluding other colonizing bacteria
and adopting the mucoid phenotype. This sequential
colonization may reﬂect the progressive selection of more
resistant bacteria during antibiotic courses. Thus, the presence
of S. aureus, S. pneumoniae or H. inﬂuenzae in sputum would be
synonymous with a less advanced lung disease, with Pa
infection being either absent or not having yet reached the
‘mucoid point’. This would be consistent with studies
highlighting the potential harmful impact of anti-staphylococcal
antibiotics resulting in earlier Pa colonization [21,22].
Persistence of Pa in sputum is the parameter most strongly
associated with mucoid transition in the present study. This is
reminiscent of the natural history of airway infection by Pa in
CF, with mucoid transition being the next, last and deﬁnitive
step after chronic Pa infection of the respiratory tract [20]. It
could then be considered that the most important beneﬁt
expected from Pa eradication therapeutics is to avoid (or at
least to postpone) mucoid transition because it is now
believed to be responsible for a major part of lung function
impairment. Other signiﬁcant predictors are divergent, but the
nature of potential risk factors assessed in the models differs,
being mainly determinant upon data availability.
Levy et al. [17] found that a 10% point FEV1% decrease is
associated with mucoid transition of Pa with a HR of 1.16.
This result is consistent with our univariate analysis, although
missing data for the youngest children prevented us from
including FEV1% in the ﬁnal multivariate model. It is also
consistent with the association between mucoid transition
and bronchodilator use, as highlighted in the present study.
We did not ﬁnd any association between mPa acquisition
and DF508 homozygote genotype, whereas the possession of
at least one DF508 CFTR allele is associated with mucoid tran-
sition in the study by Levy et al. [17]. Parad et al. [8] found that
subjects resistant to mPa infection carried at least one uncom-
mon CFTR gene allele. Details of these non-DF508 alleles
for each different study would be necessary, both to obtain a
better understanding and to allow comparison among the
studies, particularly as non-DF508 alleles may signiﬁcantly vary
in nature and distribution according to geographical region.
The natural course of CF disease is usually obscured by
treatment. Bronchodilators are prescribed in response to
airway obstruction, usually synonymous with bronchus
inﬂammation. Persistent inﬂammation may explain the link
between mucoid transition and bronchodilator use, with
mucoid phenotype being either the cause and/or the conse-
quence of inﬂammation. On the one hand, inﬂammation
generates local conditions that are likely to trigger alginate
production, as demonstrated in in vitro studies assaying
oxidative burst [11], high osmolarity [14], neutrophilic
mediators, stress response systems [23] and other
parameters. On the other hand, alginate-producing strains
are known to induce important local inﬂammation, which is
associated with lung function impairment, thus motivating
bronchodilator prescription [8,18].
Why colimycin use is associated with Pa mucoid transition
remains unclear, and few hypotheses can be suggested.
Colimycin prescription is often guided by illness severity or by
microbiological data. Mean body mass index is indeed
signiﬁcantly lower in patients receiving inhaled colimycin; these
patients receive prescriptions for signiﬁcantly more broncho-
dilators and anti-pseudomonal antibiotics (data not shown).
Colimycin would then reﬂect ‘therapeutic aggressiveness’ in
the face of more advanced and severe disease in patients with
a long history of infection and inﬂammation, thus providing
conditions favourable to mucoid transition.
Colimycin activity depends on ionic interactions with
phospholipids or bacteria [24]. Alginate coating of mucoid
colonies may interfere with colimycin penetration and action,
compromising its efﬁcacy. This selective pressure, favourable
to mucoid strains of Pa, would allow minority mucoid
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subpopulations to exceed non-mucoid ones. However, this
hypothesis is not supported by in vitro data obtained from
mPa susceptibility testing, which relates the maintainence of
mPa susceptibility to the use of colistin, as well as to other
antibiotics [25].
Lastly, direct alginate production triggered by colimycin
could be hypothesized, as previously described for other
antibiotics [26]. Further studies are warranted to investigate
the relationship between colimycin use and Pa mucoid
transition.
The main limitation of the present study is its retrospective
nature, which is the reason for the missing data, which com-
prised mainly the oldest medical records. In particular, we
were unable to ascertain the precise duration of Pa coloniza-
tion before mucoid transition. Also, we were unable to
explore the hypermutability [27–29] and adaptative traits
[29,30], and the diversity [9,31,32], of these clinical strains.
Meanwhile, retrospective data collection has allowed us to
reach a population of 52 children, along with their entire ther-
apeutic and microbiological history, and derive meaningful
results from the data.
The four factors that we identiﬁed in our population are
probably reﬂections of the clinical conditions favourable to
mucoid transition of Pa rather than direct causes of mucoid
transition. These parameters mainly express at some stage in
the evolution of CF disease and lung infection, and appear as
markers of severity. At the very least, they may be used to
identify those children who are at risk of short-term mucoid
transition of Pa, and who thus may require more frequent
monitoring, and possibly more intensive treatment. An addi-
tional component addressed in the present study is the rela-
tionship between inhaled colimycin and Pa mucoid transition,
which needs to be conﬁrmed and investigated in further
studies.
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